Trial result ·
Efficacy and Safety of Ultra-Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at men with gout who came in with acute joint inflammation. Drugs that lower uric acid can set off new flares at first. The drug tested here was febuxostat. 120 men were split by chance into group A or group B. Group A began on 10 mg a day. Group B began on 20 mg a day. In both groups, the dose then rose step by step on a set plan. The team looked at flares, uric acid levels and side effects for 24 weeks.
What they found
By week 24, both groups reached their uric acid goal about as well. Group A had fewer gout flares than group B. More people in group A had no flares at all. When other factors were weighed, group B still had more flares. The gain from the low start seemed largest in people with obesity. Liver injury of clinical concern was low in both groups. The dose of febuxostat was not linked to liver harm. A blood fat called LDL-C was linked to a liver test called ALT.
What it means for patients
The team says a start of 10 mg a day had a better safety profile. It cut early flares. It did not harm long-term uric acid control. They say this may help people at high risk, such as people with obesity.
Why it is not certain yet
The study had 120 people. All of them were men with primary gout. The abstract gives data only up to week 24. The abstract does not say if people or doctors knew who got which dose.
Source
Efficacy and Safety of Ultra-Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout.
PubMed · PMID 42704043We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Gout publications